跳转至内容
Merck
CN
  • Aldosteronoma resolution score predicts long-term resolution of hypertension.

Aldosteronoma resolution score predicts long-term resolution of hypertension.

Surgery (2014-12-03)
Anna Aronova, Benjamin L Gordon, Brendan M Finnerty, Rasa Zarnegar, Thomas J Fahey
摘要

The Aldosteronoma Resolution Score (ARS) takes into consideration four, readily available, preoperative clinical parameters in predicting the likelihood of resolution of hypertension in patients 6 months after undergoing unilateral adrenalectomy for aldosterone-producing adenoma (APA). We sought to determine the durability of this predictive model after 1 year. Sixty patients who underwent unilateral adrenalectomy for APA at a single institution between 2004 and 2013 were reviewed retrospectively. Patients who were normotensive without any antihypertensive medication requirement at greater than 1-year follow-up were considered to have complete resolution of hypertension. Forty-seven patients had data available for analysis. Median follow-up was 1,135 days (371-3,202). Forty-five percent of patients had complete resolution, 45% had improvement, and 10% had no improvement in hypertension. Applying the ARS, we found there was complete resolution of hypertension in 73% of patients with ARS 4-5, 53% of patients with ARS 2-3, and 24% of patients with ARS 0-1 compared with 75% (P = .9), 46% (P = .66), and 28% (P = .76), respectively, in the original cohort used to create the ARS. Most patients (90%) have long-term improvement or complete resolution of hypertension after unilateral adrenalectomy for APA. The ARS predicts accurately a patient's likelihood of complete resolution of hypertension beyond 1 year.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
醛固酮, ≥95% (HPLC)
Supelco
醛固酮标准液 溶液, 100 μg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®